JSW
AVDL

Journey Strategic Wealth’s Avadel Pharmaceuticals AVDL Stock Holding History

Journey Strategic Wealth’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,000
Closed -$4.5K – 211
2023
Q1 		$4.5K Hold
10,000
– – ﹤0.01% 253
2022
Q4 		$71.6K Hold
10,000
– – 0.01% 239
2022
Q3 		$50K Buy
+10,000
New +$55K 0.01% 180

Other funds holding AVDL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Journey Strategic Wealth's AVDL Position: Q2 2023 in Review

Journey Strategic Wealth sold out of Avadel Pharmaceuticals (AVDL) in Q2 2023, closing a stake of 10,000 shares — an estimated $4.5K sold.

Journey Strategic Wealth first reported a position in AVDL in Q3 2022 and held it in 3 quarters. The position peaked at $71.6K in Q4 2022. 101 funds tracked by Wall St. Rank hold AVDL as of Q2 2023.

  • Journey Strategic Wealth reported no remaining Avadel Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Journey Strategic Wealth sold 10,000 Avadel Pharmaceuticals shares in Q2 2023, an estimated $4.5K.
  • Journey Strategic Wealth first reported a position in Avadel Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Journey Strategic Wealth's Avadel Pharmaceuticals position peaked at $71.6K in Q4 2022.
  • 101 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2023.

Based on Journey Strategic Wealth's 13F filing for Q2 2023, filed 14 Aug 2023.